Newron Pharmaceuticals SpA
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more
Newron Pharmaceuticals SpA (NWRN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 21.083x
Based on the latest financial reports, Newron Pharmaceuticals SpA (NWRN) has a cash flow conversion efficiency ratio of 21.083x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF33.35 Million) by net assets (CHF1.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Newron Pharmaceuticals SpA - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Newron Pharmaceuticals SpA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Newron Pharmaceuticals SpA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Newron Pharmaceuticals SpA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai MicuRx Pharmaceutical Co. Ltd. A
SHG:688373
|
N/A |
|
TCI Co Ltd
TWO:8436
|
0.026x |
|
BFI Finance Indonesia Tbk
JK:BFIN
|
0.064x |
|
First Foundation Inc.
NYSE:FFWM
|
0.010x |
|
Southern Sun Limited
F:JK9
|
N/A |
|
Eco-Shop Marketing Berhad
KLSE:5337
|
0.095x |
|
Ningbo Daye Garden Machinery Co Ltd
SHE:300879
|
-0.191x |
|
Luoyang Northglass Technology Co Ltd
SHE:002613
|
0.040x |
Annual Cash Flow Conversion Efficiency for Newron Pharmaceuticals SpA (2005–2024)
The table below shows the annual cash flow conversion efficiency of Newron Pharmaceuticals SpA from 2005 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CHF1.46 Million | CHF-17.61 Million | -12.081x | -3663.28% |
| 2023-12-31 | CHF-29.91 Million | CHF-10.14 Million | 0.339x | -57.12% |
| 2022-12-31 | CHF-14.03 Million | CHF-11.09 Million | 0.791x | +121.46% |
| 2021-12-31 | CHF3.11 Million | CHF-11.45 Million | -3.684x | -307.54% |
| 2020-12-31 | CHF17.25 Million | CHF-15.59 Million | -0.904x | -51.35% |
| 2019-12-31 | CHF36.80 Million | CHF-21.98 Million | -0.597x | -105.27% |
| 2018-12-31 | CHF54.84 Million | CHF-15.95 Million | -0.291x | -134.45% |
| 2017-12-31 | CHF67.72 Million | CHF-8.40 Million | -0.124x | +68.48% |
| 2016-12-31 | CHF49.75 Million | CHF-19.58 Million | -0.394x | -13.58% |
| 2015-12-31 | CHF37.11 Million | CHF-12.86 Million | -0.347x | -1.43% |
| 2014-12-31 | CHF29.26 Million | CHF-10.00 Million | -0.342x | +32.56% |
| 2013-12-31 | CHF21.09 Million | CHF-10.69 Million | -0.507x | -340.15% |
| 2012-12-31 | CHF27.61 Million | CHF5.83 Million | 0.211x | +128.11% |
| 2011-12-31 | CHF6.58 Million | CHF-4.94 Million | -0.750x | +52.17% |
| 2010-12-31 | CHF12.19 Million | CHF-19.13 Million | -1.569x | -99.27% |
| 2009-12-31 | CHF29.28 Million | CHF-23.06 Million | -0.787x | -80.96% |
| 2008-12-31 | CHF45.81 Million | CHF-19.93 Million | -0.435x | -80.11% |
| 2007-12-31 | CHF57.40 Million | CHF-13.87 Million | -0.242x | -70.22% |
| 2006-12-31 | CHF67.86 Million | CHF-9.63 Million | -0.142x | +83.14% |
| 2005-12-31 | CHF17.02 Million | CHF-14.33 Million | -0.842x | -- |